• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

8 Questions on Diabetes Drugs for Cardioprotection

Slideshow

Slideshow

Cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) have been reported in a number of high-profile, landmark clinical trials.

Take this quick quiz to test your knowledge of key findings.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024 / Image credit: ©Rasi/AdobeStock

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

Sydney Jennings
October 23rd 2024
Article

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Elinzanetant Data from Bayer Feature Prominently at 19th World Congress on Menopause / image courtesy of Bayer

Elinzanetant Data from Bayer Feature Prominently at 19th World Congress on Menopause

Grace Halsey
October 17th 2024
Article

Bayer announced 12 presentations focused on symptoms of menopause and effects of its investigational oral nonhormonal medication elinzanetant.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List / image credit Mounjaro: ©MK Photo/stock.adobe.com

FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List

Ashley Gallagher;Grace Halsey
October 15th 2024
Article

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

October Issue of Patient Care Online Supplement is Now Live

October Issue of Patient Care Online Supplement is Now Live

Sydney Jennings
October 14th 2024
Article

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

© 2024 MJH Life Sciences

All rights reserved.